Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

被引：0
作者：
Li, Shuluan [1 ,2 ]
Zhang, Pei [3 ]
Wang, Tianyu [2 ,4 ]
Wang, Jie [3 ]
Duan, Jianchun [3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol Natl,Canc Ctr, Shenzhen 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Dept Breast Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China
来源：
THORACIC CANCER | 2021年 / 12卷 / 23期
关键词：
ALK; brigatinib; chemotherapy; lung squamous cell carcinoma; 1ST-LINE CRIZOTINIB; OPEN-LABEL; CANCER; ROS1;
D O I：
10.1111/1759-7714.14133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK-positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first-line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.
引用
收藏
页码：3273 / 3276
页数：4
相关论文
共 50 条
  • [1] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
    Mamesaya, Nobuaki
    Nakashima, Kazuhisa
    Naito, Tateaki
    Nakajima, Takashi
    Endo, Masahiro
    Takahashi, Toshiaki
    BMC CANCER, 2017, 17
  • [2] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [3] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [4] The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer
    Amanam, Idoroenyi
    Gupta, Rohan
    Mambetsariev, Isa
    Salgia, Ravi
    FUTURE ONCOLOGY, 2018, 14 (19) : 1897 - 1908
  • [5] Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
    Zheng, Yuan
    Zhu, Wei
    Huang, Xinjie
    Lin, Dongqun
    Lin, Yu
    OPEN LIFE SCIENCES, 2021, 16 (01): : 838 - 844
  • [6] Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
    Kobayashi, Takayuki
    Uehara, Yuji
    Watanabe, Kageaki
    Hishima, Tsunekazu
    Hosomi, Yukio
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (07):
  • [7] Brigatinib, a new treatment option in ALK-rearranged advanced non-small cell lung carcinoma
    Leprieur, Etienne Giroux
    Wislez, Marie
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S173 - S176
  • [8] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) : 2027 - 2039
  • [9] A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations
    Alrifai, Doraid
    Popat, Sanjay
    Ahmed, Merina
    Gonzalez, David
    Nicholson, Andrew G.
    du Parcq, John
    Benepal, Tim
    LUNG CANCER, 2013, 80 (03) : 339 - 340
  • [10] Synchronous primary lung sarcomatous carcinoma and lung squamous cell carcinoma: a case report
    Zhao, Maoyuan
    Jing, Qiuyang
    Hui, Zhouguang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (03): : 480 - 483
12345